Stoke Therapeutics (STOK) Assets Average (2019 - 2026)

Stoke Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $430.9 million for Q1 2026.

• On a quarterly basis, Assets Average rose 27.01% year-over-year to $430.9 million in Q1 2026; TTM through Mar 2026 was $430.9 million, a 27.01% increase from a year earlier, with the FY2025 full-year figure at $345.0 million, up 38.03% from the prior year.
• Assets Average advanced to $430.9 million in Q1 2026 per STOK's latest filing, from $389.3 million in the prior quarter.
• Across five years, Assets Average topped out at $430.9 million in Q1 2026 and bottomed at $216.8 million in Q1 2024.
• The 5-year median for Assets Average is $282.4 million (2024), against an average of $302.8 million.
• Across the five-year window, Assets Average dropped 19.4% in 2024 and soared 56.49% in 2025, its largest moves.
• Year by year, Assets Average stood at $266.8 million in 2022, then fell by 12.27% to $234.1 million in 2023, then gained by 20.64% to $282.4 million in 2024, then jumped by 37.85% to $389.3 million in 2025, then grew by 10.66% to $430.9 million in 2026.
• Per Business Quant, the three latest STOK Assets Average figures stand at $430.9 million (Q1 2026), $389.3 million (Q4 2025), and $372.4 million (Q3 2025).